A Randomized, Double Blind, Placebo Controlled, Phase III Study of KUC-7483 in Patients With Overactive Bladder.
Phase of Trial: Phase III
Latest Information Update: 26 Jul 2010
At a glance
- Drugs Ritobegron; Tolterodine
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Kissei Pharmaceutical
- 26 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Jul 2010 Interim results released in a Kissei Pharmaceuticals media release. The company intends to perform a detailed analysis prior to making a decision regarding further development of KUC 7483.
- 02 Jul 2010 Primary endpoint 'Micturition rate' has not been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History